Tyson Nickelson
Nurse Practitioner · Manhattan, KSNPI 1972194751
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,073 of the $8,176 with a category attached, or 62.0%. 31 manufacturers reported payments, led by Angiodynamics, Inc. at 36.7% of the total. Reporting peaked in 2024 at $3,008 and has fallen 73.0% since, to $812 in 2025. Among nurse practitioner clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 329 payments — averaging $24.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$3K
- AstraZeneca$614
- E.r. Squibb & Sons, L.L.C.$568
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$522
- Novartis$503
- Amgen$480
- plus $2K from 25 others
What the payments were for
- Food & beverage$5,07362%
- Education$1031%
- Other$3,00037%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 2 | $3,000 |
| AstraZeneca | 33 | $614 |
| E.r. Squibb & Sons, L.L.C. | 46 | $568 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 38 | $522 |
| Novartis | 45 | $503 |
| Amgen | 32 | $480 |
| Merck | 23 | $380 |
| Actelion Pharmaceuticals US, Inc. | 15 | $365 |
| Boehringer Ingelheim | 21 | $362 |
| Pfizer | 12 | $207 |
| Johnson & Johnson | 16 | $201 |
| Medtronic | 6 | $113 |
| Novo Nordisk | 5 | $104 |
| Kiniksa Pharmaceuticals, Ltd. | 5 | $99 |
| Abbott | 4 | $74 |
| Bayer | 3 | $63 |
| Regeneron Healthcare Solutions, Inc. | 3 | $58 |
| Alnylam Pharmaceuticals Inc. | 2 | $52 |
| Cvrx, Inc. | 2 | $52 |
| Boston Scientific | 1 | $50 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| Inari Medical, Inc. | 1 | $46 |
| Tactile Systems Technology Inc | 1 | $45 |
| Scpharmaceuticals Inc. | 2 | $38 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Lantheus Medical Imaging, Inc. | 1 | $20 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $20 |
| Sanofi | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Smith+Nephew | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,176 in reported general payments places this provider in the 95th percentile of 1,326 nurse practitioner providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 55 | $58,410 |
| JardianceEmpagliflozin | 64 | $45,238 |
| EliquisApixaban | 45 | $31,109 |
| VerquvoVericiguat | 21 | $15,453 |
| XareltoRivaroxaban | 19 | $14,258 |
| FarxigaDapagliflozin Propanediol | 21 | $11,879 |
| Flecainide Acetate | 29 | $1,366 |
| Amiodarone Hcl | 53 | $1,158 |
| Metoprolol Succinate | 107 | $1,055 |
| Nebivolol Hcl | 32 | $1,009 |
| Ezetimibe | 23 | $598 |
| ClopidogrelClopidogrel Bisulfate | 49 | $554 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 40 | $510 |
| Dofetilide | 13 | $497 |
| Losartan Potassium | 45 | $496 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $503 | $58,41055 claims |
| Boehringer IngelheimJardiance | $362 | $45,23864 claims |
| PfizerEliquis | $207 | $31,10945 claims |
| MerckVerquvo | $380 | $15,45321 claims |
| Johnson & JohnsonXarelto | $201 | $14,25819 claims |
| AstraZenecaFarxiga | $614 | $11,87921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,326 nurse practitioner providers in Kansas.
Other nurse practitioner in Manhattan
- Kaitlyn WilsonManhattan$7K
- Gary GrafTopeka$726K
- Anna ShortRoeland Park$215K
- Shannon GreggTopeka$140K
- Morteza RabiiOverland Park$88K
- Constance JacobWichita$65K
- Michelle KirkHutchinson$58K
- Catherine PowellWichita$50K
- Lori RanalloWestwood$48K
- Kristyn MilburnPleasanton$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.